Key result
Broadening the marketing licence for nicotine replacement therapy to patients with cardiovascular disease did not increase prescribing rates, which were approximately 1500 per 100,000 smokers per month.
Why the study?
Does broadening the marketing licence for nicotine replacement therapy increase prescribing rates for patients with cardiovascular disease?
Observational
Yes
Does broadening the marketing licence for nicotine replacement therapy increase prescribing rates for patients with cardiovascular disease?
Broadening the marketing licence for nicotine replacement therapy to include patients with cardiovascular disease did not increase prescribing rates in this population.
Licence broadening did not increase NRT prescribing in CVD; leaves open barriers to uptake and need for targeted strategies.
AIMS: In November 2005 the indications for nicotine replacement therapy (NRT) were broadened in the United Kingdom, making all forms available to patients with stable cardiovascular disease (CVD). This study aimed to estimate the effects of this change on prescribing of NRT to CVD patients in England. DESIGN: Segmented regression analysis of time series of monthly rates of prescribing of NRT. SETTING: A total of 350 general practices in England included in The Health Improvement Network (THIN), a database of UK electronic primary care records. PARTICIPANTS: All adult patients with coronary heart disease (CHD) or stroke registered with a THIN practice in England. MEASUREMENTS: The number of patients per 100,000 with CHD and stroke that received a prescription for NRT each month between January 2002 and June 2009. FINDINGS: Approximately 1500 per 100,000 smokers with CVD were prescribed NRT per month. Prescribing of NRT to CHD and stroke patients increased until the end of 2005 and subsequently decreased, with no immediate change following the Medicines and Healthcare Regulatory Authority (MHRA) licensing change. CONCLUSIONS: Broadening the marketing licence in the United Kingdom for nicotine replacement therapy to allow it to be prescribed to patients with CVD did not increase prescribing rates for this group of patients.
No takes yet. Share an insight, caveat, or question.
Langley et al. (2012) conducted an observational in Coronary heart disease or stroke. Broadening of marketing licence for nicotine replacement therapy vs. Pre-licensing change period was evaluated on Monthly rates of prescribing of NRT per 100,000 patients with CHD and stroke. Broadening the marketing licence for nicotine replacement therapy to patients with cardiovascular disease did not increase prescribing rates, which were approximately 1500 per 100,000 smokers per month.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: